Akèy › Neuroblastom › Texas
Etid klinik pou Neuroblastom nan Texas
15 etid pou Neuroblastom ap chèche patisipan nan sit nan Texas.
Vil nan Texas
Tèks ofisyèl etid la (Anglè)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- Medical City Dallas Hospital, Dallas
- ak 10 plis
Ap rekriteFaz 3
Jiska laj 30 · Tout sèks · Mizajou Oct 2, 2026 · NCT06172296Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Ap rekriteFaz 2
Jiska laj 22 · Tout sèks · Mizajou Sep 4, 2026 · NCT02559778Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Children's Medical Center, Dallas
Ap rekriteFaz 1/2
Jiska laj 26 · Tout sèks · Mizajou Sep 3, 2026 · NCT06465199Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Medical Center, Dallas
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Sep 3, 2026 · NCT06541262Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
- Children's Medical Center, Dallas
Ap rekriteFaz 2
Laj 1 a 21 · Tout sèks · Mizajou Sep 3, 2026 · NCT06540963Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Dell Children's Medical Center of Central Texas, Austin
- Driscoll Children's Hospital, Corpus Christi
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- ak 8 plis
Ap rekriteFaz 3
365 Days – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- Dell Children's Blood and Cancer Center, Austin
Ap rekriteFaz 2
12 Months – 21 Years · Tout sèks · Mizajou Aug 12, 2026 · NCT05489887PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Texas Children's Hospital, Houston
Ap rekriteFaz 1/2
Laj 1 a 30 · Tout sèks · Mizajou Jul 22, 2026 · NCT06721689NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 1 a 24 · Tout sèks · Mizajou Jul 21, 2026 · NCT07211737NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center, Fort Worth
Ap rekriteFaz 2
Laj 1 a 31 · Tout sèks · Mizajou Jul 20, 2026 · NCT06450041Neuroblastoma Biology Study
- University of Texas Southwestern, Dallas
- Cook Children's Medical Center - Fort Worth, Fort Worth
Ap rekriteEtid obsèvasyon
31 Days – 99 Years · Tout sèks · Mizajou Mar 23, 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- University of Texas Southwestern Medical Center, Dallas
Ap rekrite
Jiska laj 17 · Tout sèks · Mizajou Feb 10, 2026 · NCT06831552GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
- Texas Children's Hospital, Houston
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Sep 19, 2025 · NCT03294954Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.